Hidrasec (Racecadotril)

Hidrasec is indicated for the symptomatic treatment of acute, non‑bloody diarrhea, helping to reduce stool frequency and fluid loss. It is commonly selected when a non‑opioid, non‑anticholinergic option is preferred for short‑term management.

• Acute watery diarrhea in adults and children
• Diarrhea associated with viral gastroenteritis
• Diarrhea secondary to food‑borne infections
• Symptomatic relief during travel‑related gastrointestinal upset
• Adjunct therapy in mild to moderate dehydration when rehydration is ongoing

• Racecadotril is an enkephalinase inhibitor that prevents the breakdown of endogenous enkephalins in the intestinal mucosa. By preserving enkephalin activity, it reduces the secretion of water and electrolytes into the intestinal lumen, thereby decreasing stool volume without altering intestinal motility or absorption processes.

Adverse reactions to Hidrasec are generally uncommon, but they can be categorized by frequency and severity.

Common

• Nausea
• Headache
• Abdominal discomfort
• Flatulence
• Mild skin rash

Serious

• Allergic reactions such as urticaria or angioedema
• Severe skin eruptions (e.g., Stevens‑Johnson syndrome)
• Hepatic enzyme elevation (rare)
• Anaphylactic shock (extremely rare)

Before using Hidrasec, consider the following safety points:

• Verify that diarrhea is non‑bloody and not caused by invasive bacterial infection.
• Use caution in patients with known hypersensitivity to racecadotril or any excipients.
• Assess renal or hepatic impairment, as dose adjustment may be required.
• Do not substitute for rehydration therapy; ensure adequate fluid and electrolyte replacement.
• Consult a healthcare professional if diarrhea persists longer than 48 hours or is accompanied by fever.
• Pregnant or breastfeeding individuals should seek medical advice before use.

Potential drug interactions with Hidrasec are limited, but certain combinations warrant attention.

Avoid

• Concomitant use with potent enkephalinase inhibitors that may amplify effects.
• Co‑administration with drugs that significantly alter gastrointestinal motility, as efficacy may be reduced.

Use with caution

• Antihypertensive agents, because fluid shifts could affect blood pressure control.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs), which may increase risk of gastrointestinal irritation.
• Other antidiarrheal agents (e.g., loperamide) to avoid excessive reduction of gut motility.
• Medications metabolized by hepatic enzymes that could be competitively inhibited.